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Figure. Panel A shows the median number and range of sjTREC copies/10^5 T cells plotted on the left Y-axis and shown using ﬁlled squares and solid lines. The
median and range of TCR Vb spectrotype complexity score (SCS) is plotted on the right Y-axis and shown using open circles and dashed lines. A normal SCS is equal to
184 (Wu CJ et al., Blood 2000). Panel B shows a representative TCR Vb repertoire pre- and post-UCBT.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90 S89100
Allogeneic Stem Cell Transplant Offers Cure for
Intractable Childhood Enteropathy
Austen J.J. Worth 1, Zohreh Nademi 2, Jochen Kammermeier 3,
Su Bunn 4, Robert Chiesa 5, Andrew Cant 6, Sophie Hambleton 7,
Neil Shah 8, Mary Slatter 9, Kanchan Rao 10, Andrew Gennery 11,
Mamoun Elawad 3, Persis Amrolia 12, Paul Veys 13. 1Department
of Immunology, Great Ormond Street Hospital for Children,
London, United Kingdom; 2Department of Bone Marrow
Transplantation, Great North Childrens Hospital, Newcastle,
United Kingdom; 3Department of Gastroenterology, Great
Ormond Street Hospital, London, United Kingdom;
4Department og Gastroenterology, Great North Childrens
Hospital, Newcastle, United Kingdom; 5Department of Bone
Marrow Transplantation, Great Ormond Street Hospital,
London, United Kingdom; 6Department of Paediatrics
Immunology, Newcastle General Hospital, Newcastle upon
Tyne, United Kingdom; 7Department of Immunology, Great
North Childrens Hospital, Newcastle, United Kingdom; 8GreatOrmond Street Hospital, London, United Kingdom; 9Newcastle
upon Tyne Hospitals NHS Foundation Trust, Newcastle upon
Tyne, United Kingdom; 10Great Ormond Street Hospital,
London, ., UK; 11Paediatric Immunology, Newcastle University,
Newcastle upon Tyne, United Kingdom; 12Great Ormond St
Children`s Hospital, London, GB; 13Great Ormond Street
Hospital for Children, London, United Kingdom
Early onset inﬂammatory bowel disease and other intractable
enteropathies of childhood (IEOC) comprise a heterogenous
range of genetically deﬁned and undeﬁned conditions, asso-
ciated with immune dysregulation. These disorders have an
extremely poor prognosis and are associatedwith poor quality
of life and a high mortality from the complications of parental
nutrition +/- prolonged immunosuppressive therapy. Given
emerging data that many of these patients have an underlying
genetic disorder of immune regulation, we have developed a
UK National Commissioning Group programme of allogeneic
stem cell transplant (SCT) for IEOC. We now report initial data
on this novel indication for SCT.
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between 1999 and 2013. All patients had onset of symp-
toms before 7 years of age and were either TPN dependent
(n¼13) or had enteropathy refractory to at least 3 immu-
nosuppressive agents (n¼13) prior to transplant. Patients
with overt primary immunodeﬁciency were excluded. 8 of
26 patients had a conﬁrmed pathogenic mutation identi-
ﬁed (IPEX, XIAP, IL10, IL10Ra) and 18/26 remain gene-
tically undeﬁned. 11 patients (42%) had previously
undergone gut resections +/- defunctioning stoma for-
mation and 63% had suffered life threatening complica-
tions prior to transplant (sepsis, lymphoproliferative
disease, vasculitis).
22 SCTs were performed with fully HLA matched donors (8
family, 14 unrelated), and 5 with 9/10 mismatched donors.
With exception of 2 sibling donor grafts conditioned, all
patients received reduced toxicity conditioning, the ma-
jority with alemtuzumab 1mg/kg, ﬂudarabine 150mg/m2 +
either treosulphan 42g/m2 (n¼12) or melphalan 140mg/m2
(n¼10). Transplant related mortality was 23% (n¼6) from
GVHD, conditioning toxicity, viral infections and pulmonary
hypertension. One patient died from diabetic ketoacidosis
unrelated to SCT following a successful transplant. 96% of
patients engrafted, but one patient required a second graft
following rejection. The majority of patients (22/26) had full
donor chimerism at last follow-up, and the remaining 4
patients have stable mixed chimerism with 73-94% donor
chimerism within the lymphoid lineage. 8 patients (30%)
developed signiﬁcant aGVHD but the incidence of cGVHD
was low (n¼1, 4%).
At amedian follow-up of 51months,19 patients are alive,17 of
whom have had sustained improvement in their enteropathy.
8 surviving patients (89%) on TPN pre-transplant have now
discontinued and 14 (78%) are off all immunosuppression.
Our data demonstrate that reduced toxicity conditioned SCT
can cure the majority of patients with IEOC even in the
absence of a deﬁned genetic defect. We believe that given the
severity of this condition, SCT offers patients major improve-
ment in quality of life at an acceptable risk of toxicity and thatfurther studies of this approach in well-deﬁned patients are
warranted.SOLID TUMORS101
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Background: High-dose chemotherapy (HDCT) can achieve
durable remissions in 30-60% of GCT patients (pts) requiring
salvage treatment. This Phase I/II study investigated safety
and efﬁcacy of a novel high-dose regimen (TI-TIC) in this
population.
Methods: Pts age 18 with GCT and progression after 1
cisplatin-based regimen were eligible. TI-TIC consists of 1-
2 cycles of conventional-dose paclitaxel plus ifosfamide
(TI) q14-21 days followed by 3 cycles of high-dose TIC
with ASCT q21-28 days. TI dosing was constant. In Phase I,
high-dose TIC was administered in 1 of 5 cohorts (I: 6, 8 or
10g/m2; T: 200 or 250mg/m2; C: AUC¼21 or 24) using a
standard 3+3 dose escalation design to determine the
maximal tolerated dose (MTD). In Phase II, Simon’s 2-
stage optimal design was used to estimate the complete
response (CR) rate at MTD.
Results: Of 26 pts (25 male; median age 31; 21 non-
seminoma, 5 seminoma) enrolled, 23 received 1 cycle of
high-dose TIC. Primary sites included testis (n¼15), medi-
astinum (n¼6), other (5). In Phase I, 0/18 pts had dose-
limiting toxicity (DLT) during TIC cycle 1, making cohort 5 (T
250mg/m2, I 10g/m2, C AUC¼24) the MTD. Toxicities were
similar to those reportedwith TI-CE (Feldman JCO 2010) with
little variation across cohorts. However, 2/18 pts in Phase I (1
in cohort 4, 1 in cohort 5) developed grade 3 acute renal
insufﬁciency after TIC cycles 1 and 2 (cycle 3 not given). Both
later developed chronic renal insufﬁciency with 1 pt
requiring dialysis 10 months after TI-TIC. A third pt treated in
Phase II developed a similar acute and then chronic renal
insufﬁciency pattern with TIC cycles 1 and 2. In Phase II, 7/11
evaluable pts (64%, 90% one-sided CI 40%-100%) achieved a
CR,1 had a partial responsewith negativemarkers, and 3 had
incomplete responses. Although the CR rate was sufﬁcient to
move to the second Simon’s stage, renal toxicity led to pre-
mature trial closure.
Conclusions: Although there was preliminary evidence of
efﬁcacy, high dose TI-TIC was associated with acute and
chronic renal insufﬁciency. TI-CE remains the standard
high dose regimen for salvage treatment of GCT at MSKCC.
